Latest receivables for IPAH: $14M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Interpharm Holdings's receivables stands at $14M as of December 2007. That compares with $11M in the prior-year period — up 20.9% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Interpharm Holdings reported $14M in receivables versus $11M a year earlier — a 20.9% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.
That compares with $11M in the prior-year period — up 20.9% year over year. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.
The history chart shows how Interpharm Holdings's receivables evolved across reporting periods, while the comparison chart places IPAH next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.